HC Wainwright Issues Positive Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price

SAB Biotherapeutics (NASDAQ:SABS) had its price target increased by analysts at HC Wainwright from $7.00 to $10.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 178.94% from the stock’s previous close.

A number of other research firms have also weighed in on SABS. Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Rodman & Renshaw reiterated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday. Chardan Capital boosted their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Zacks Research lowered shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

SAB Biotherapeutics Price Performance

SABS stock traded down $0.14 during trading on Tuesday, reaching $3.59. 577,659 shares of the company were exchanged, compared to its average volume of 648,922. The company has a 50-day moving average of $3.87 and a two-hundred day moving average of $3.81. The company has a market capitalization of $182.66 million, a price-to-earnings ratio of -1.56 and a beta of 0.55. SAB Biotherapeutics has a twelve month low of $1.60 and a twelve month high of $6.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, equities analysts predict that SAB Biotherapeutics will post -1.1 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

A number of large investors have recently added to or reduced their stakes in SABS. Vivo Capital LLC purchased a new stake in SAB Biotherapeutics during the third quarter worth about $22,954,000. Commodore Capital LP purchased a new stake in SAB Biotherapeutics during the third quarter worth about $8,847,000. RA Capital Management L.P. purchased a new stake in SAB Biotherapeutics during the third quarter worth about $8,847,000. Woodline Partners LP bought a new position in SAB Biotherapeutics during the third quarter worth about $5,730,000. Finally, Spruce Street Capital LP bought a new position in SAB Biotherapeutics during the fourth quarter worth about $8,222,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.